Clinical Director, Cancer Center, Beth Israel Deaconess Medical Center
Oncology
Dr. Lowell E. Schnipper, MD
|
|
Give Review
Lowell Schnipper works in the field of Oncology. He graduated from State University of New York Downstate Medical Center College of Medicine. He has 6 awards "America's Top Doctors", "Boston Magazine", "America's Top Doctors for Cancer", "Fellow (FASCO)", "Top MD" and "Super Doctor". Dr. Lowell E. Schnipper is also a published physician. He has 101 publication published. The most recent publication is: Genetic analysis of adenovirus E1A: induction of genetic instability and altered cell morphologic and growth characteristics are segregatable functions. He is registered with Medicare and accepts Medicare payments.
Publications
- Quality oncology practice initiative: an approach to solving the value equation.
- American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes.
- Translating clinical trials into meaningful outcomes.
- Value and Cancer care: toward an equitable future.
- ASCO Task Force on the Cost of Cancer Care.
- ASCO Addresses the Rising Cost of Cancer Care.
- Update in oncology.
- ASCO core values.
- Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.
- The costs of conDucting clinical research.
- In vitro and in vivo inDuction of antiangiogenic activity by plasminogen activators and captopril.
- Cancer survivorship issues for minority and underserved populations.
- A model state act to authorize and regulate physician-assisted suicide.
- Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.
- Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic Cancer translate into clinical significance and value?
- Commentary: should cost and comparative value of treatments be considered in clinical practice guidelines?
- A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
- Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study.
- Enhancement of superoxide anion release by granulocytes harvested from patients receiving granulocyte-macrophage colony-stimulating factor.
- A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.
- Bone marrow autotransplantation for solid Tumors--prospects.
- Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor Cell compartment in man.
- Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo.
- Clinical implications of tumor-Cell heterogeneity.
- Pharmacokinetics and immediate effects of high-dose carmustine in man.
- Ribavirin treatment of the acquired immunodeficiency syndrome (AIDS) and the acquired-immunodeficiency-syndrome-related complex (ARC). A phase 1 study shows transient ...
- High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast Cancer.
- Prolonged cytogenetic and hematologic remission of blastic transformation in chronic granulocytic Leukemia.
- Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA from herpes simplex virus resistant to 9-beta-D-arabinofuranosyladenine.
- Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on the proliferation of herpes simplex virus type 1-transformed and thymidine kinase-deficient mouse Cells.
- Induced hemorrhagic hypotension. Its effect on plasma 5-hydroxytryptamine and plasma 5-hydroxyindole acetic acid levels.
- The use of G-CSF or GM-CSF mobilized peripheral blood progenitor Cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose c...
- High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's Disease: a prognostic model for treatment outcomes.
- Trials of 9-amino-20(S)-camptothecin in Boston.
- Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast Cancer: no improvement in progression-free survival by the sequence of high-...
- High-dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung Cancer.
- High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem Cell support: safety and future directions.
- High-dose chemotherapy with autologous stem cell support for breast Cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
- Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast Cancer.
- Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem Cell support.
- Dose-intensive therapy for limited-stage small-cell lung Cancer: long-term outcome.
- Genetic analysis of adenovirus E1A: induction of genetic instability and altered Cell morphologic and growth characteristics are segregatable functions.
- Neutropenic enterocolitis as a complication of high dose chemotherapy with stem Cell rescue in patients with solid tumors: a case series with a review of the literature.
- Dose escalation of the hypoxic Cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem Cell support.
- High-dose multimodality therapy with autologous stem-Cell support for stage IIIB breast carcinoma.
- American Society of Clinical Oncology guidance statement: the cost of Cancer care.
- American society of clinical oncology statement: toward individualized care for patients with advanced Cancer.
- Cloning and characterization of the 5''-flanking sequence for the human DNA topoisomerase II beta gene.
- Winning the war on Cancer.
- Molecular cloning and characterization of the promoter for the Chinese hamster DNA topoisomerase II alpha gene.
- High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast Cancer responding to standard-dose therap...
- Passage to nonselective media transiently alters growth of mycophenolic acid-resistant mammalian Cells expressing the escherichia coli xanthine-guanine phosphoribosylt...
- DNA topoisomerase II alpha expression is associated with alkylating agent resistance.
- Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian Cells.
- Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary Cell line.
- Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's Disease refractory to chemotherapy.
- Adjuvant chemotherapy for breast Cancer.
- Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol.
- Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir.
- Repair of DNA following incorporation of 1-beta-D-arabinofuranosylcytosine into herpes simplex virus type 1.
- Resistance of herpes simplex virus to 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine: physical mapping of drug synergism within the viral DNA polymerase locus.
- Plasma serotonin levels during total cardiopulmonary bypass.
- Plasma serotonin levels and arfonad-induced hypotension.
- Nonlymphomatous malignant tumors complicating Hodgkin''s Disease. Possible association with intensive therapy.
- Enhanced survival of ultraviolet-irradiated herpes simplex virus in Cells exposed to antiviral agents.
- Resistance of herpes simplex virus to adenine arabinoside and E-5-(2-bromovinyl)-2'-deoxyuridine: a physical analysis.
- Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient.
- Genetic mechanisms of resistance to acyclovir in herpes simplex virus.
- The Epstein-Barr virus and human lymphoproliferative Disorders.
- Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir.
- Inhibition of herpes simplex virus transformed and nontransformed Cells by acycloguanosine: mechanisms of uptake and toxicity.
- Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci.
- Photodynamic inactivation of herpes simplex virus by hematoporphyrin derivative and light.
- Mechanisms of photodynamic inactivation of herpes simplex viruses: comparison between methylene blue, light plus electricity, and hematoporhyrin plus light.
- Virus replication and inDuction of interferon in human epidermal keratinocytes following infection with herpes simplex virus.
- Induction of Cellular DNA synthesis by the nondefective Adenovirus 2-Simian virus 40 hybrid viruses.
- Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. VI. Characterization of the DNA from five nondefective hybrid viruses.
- Effects of alpha and beta interferons on cultured human keratinocytes.
- Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy.
- The crisis in clinical Cancer research. Third-party insurance and investigational therapy.
- Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support.
- Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
- Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.
- Effects of Bloom's syndrome fibroblasts on genetic recombination and mutagenesis of herpes simplex virus type 1.
- Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and mutagenesis of herpes simplex virus type 1.
- Effect of novobiocin on the antitumor activity and tumor Cell and bone marrow survivals of three alkylating agents.
- The effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on DNA repair and mutagenesis of herpes simplex virus type 1.
- Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions.
- Gene activation by induced DNA rearrangements.
- Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's Disease and non-Hodgkin's lymphoma: a dose-finding study.
- Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary Cells and in an epipodo...
- A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.
- Viral infections and Cancer.
- A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity.
- Cisplatin, continuous-infusion 5-fluorouracil, and intermediate-dose methotrexate in the treatment of unresectable non-small Cell carcinoma of the lung.
- A phase I trial of continuous-infusion cyclophosphamide in refractory Cancer patients.
- A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast Cancer responding to ...
- Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid Tumors with autologous marrow transplant: an analysis of four chemotherapy regimens.
- Oncogenes result in genomic alterations that activate a transcriptionally silent, dominantly selectable reporter gene (neo).
- The role of chemotherapy in the management of Malignant urogenital neoplasms.
Schools
SUNY Downstate Medical Center College Of Medicine
Yale New Haven Hospital
National Cancer Institute Nih
Washington University
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- America's Top Doctors for Cancer
- Fellow (FASCO)
- Top MD
- Super Doctor
Education
-
Yale-New Haven Hospital -
State University of New York Downstate Medical Center College of Medicine
Hospital
-
Beth Israel Deaconess Medical Center
Drug Facts
| NPI NUMBER | 1861414278 | |
| NPPES Provider LastName | SCHNIPPER | |
| NPPES Provider FirstName | LOWELL | |
| NPPES Provider ZIPCode | 02215 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 108.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1861414278 |
| Last Name Of The Provider | SCHNIPPER |
| First Name Of The Provider | LOWELL |
| View All |
Similar Doctors
|
|
Dr. Geoffrey Liu, MD |
|
|
Dr. Craig C. Earle, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ronald W. Takvorian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ruth M. Ruprecht, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Pallavi Kumar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nageatte Ibrahim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel Buchsbaum, MD
This Doctor is OpenDoctor Recommended.
|